Home › 2026-16837
Determining Whether To Submit an ANDA or a 505(b)(2) Application; Draft Guidance for Industry; Availability
Read on FederalRegister.gov · Official PDF · Docket on Regulations.gov · Submit a comment · Add to calendar (.ics)
Summary (from the Federal Register abstract)
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled "Determining Whether to Submit an ANDA or a 505(b)(2) Application." This draft guidance is intended to serve as a foundational guidance to assist applicants in determining which one of the abbreviated approval pathways under the Federal Food, Drug, and Cosmetic Act (FD&C Act) is appropriate for the submission of a marketing application to FDA. This draft guidance revises the guidance for industry titled "Determining Whether to Submit an ANDA or a 505(b)(2) Application" issued in May 2019 and, when finalized, will replace the 2019 guidance for industry.
- Document type
- Notice
- Federal Register document number
- 2026-16837
- Published
- Aug 18, 2026
- Action
- Notice of availability.
- Docket
- FDA-2017-D-5974
- Comments posted on Regulations.gov (at last check)
- 0
- DATES section (from the document)
- Submit either electronic or written comments on the draft guidance by October 19, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
- Topics (auto-tagged)
- Other FDA topics
Source: Federal Register API, document 2026-16837. Federal Register text is a U.S. government work. Confirm dates in the official document; later documents may extend, reopen or correct them.